Research ExplorerPublicationsMetronomic scheduling of trofosfamide chemotherapy in human ...

Metronomic scheduling of trofosfamide chemotherapy in human NSCLC xenografts highly increases therapeutic efficacy compared to conventional scheduling by inhibition of angiogenesis.

Standard

Metronomic scheduling of trofosfamide chemotherapy in human NSCLC xenografts highly increases therapeutic efficacy compared to conventional scheduling by inhibition of angiogenesis. / Stölting, S; Klink, Thorsten; Bela, C; Engels, C; Wagner, T.

In: INT J CLIN PHARM TH, Vol. 42, No. 11, 11, 2004, p. 652-653.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Stölting, S, Klink, T, Bela, C, Engels, C & Wagner, T 2004, 'Metronomic scheduling of trofosfamide chemotherapy in human NSCLC xenografts highly increases therapeutic efficacy compared to conventional scheduling by inhibition of angiogenesis.', INT J CLIN PHARM TH, vol. 42, no. 11, 11, pp. 652-653. <http://www.ncbi.nlm.nih.gov/pubmed/15598036?dopt=Citation>

APA

Stölting, S., Klink, T., Bela, C., Engels, C., & Wagner, T. (2004). Metronomic scheduling of trofosfamide chemotherapy in human NSCLC xenografts highly increases therapeutic efficacy compared to conventional scheduling by inhibition of angiogenesis. INT J CLIN PHARM TH, 42(11), 652-653. [11]. http://www.ncbi.nlm.nih.gov/pubmed/15598036?dopt=Citation

Vancouver

Stölting S, Klink T, Bela C, Engels C, Wagner T. Metronomic scheduling of trofosfamide chemotherapy in human NSCLC xenografts highly increases therapeutic efficacy compared to conventional scheduling by inhibition of angiogenesis. INT J CLIN PHARM TH. 2004;42(11):652-653. 11.

Bibtex

@article{c4599884bb3e4ea0aababe543670470c,
title = "Metronomic scheduling of trofosfamide chemotherapy in human NSCLC xenografts highly increases therapeutic efficacy compared to conventional scheduling by inhibition of angiogenesis.",
keywords = "Animals, Humans, Mice, Tumor Cells, Cultured, Drug Administration Schedule, Mice, Nude, Transplantation, Heterologous, Lung Neoplasms/*drug therapy, Antineoplastic Agents, Alkylating/administration & dosage/*therapeutic use, Carcinoma, Non-Small-Cell Lung/*drug therapy, Cyclophosphamide/administration & dosage/*analogs & derivatives/*therapeutic use, Neovascularization, Pathologic/*prevention & control, Animals, Humans, Mice, Tumor Cells, Cultured, Drug Administration Schedule, Mice, Nude, Transplantation, Heterologous, Lung Neoplasms/*drug therapy, Antineoplastic Agents, Alkylating/administration & dosage/*therapeutic use, Carcinoma, Non-Small-Cell Lung/*drug therapy, Cyclophosphamide/administration & dosage/*analogs & derivatives/*therapeutic use, Neovascularization, Pathologic/*prevention & control",
author = "S St{\"o}lting and Thorsten Klink and C Bela and C Engels and T Wagner",
year = "2004",
language = "English",
volume = "42",
pages = "652--653",
number = "11",

}

RIS

TY - JOUR

T1 - Metronomic scheduling of trofosfamide chemotherapy in human NSCLC xenografts highly increases therapeutic efficacy compared to conventional scheduling by inhibition of angiogenesis.

AU - Stölting, S

AU - Klink, Thorsten

AU - Bela, C

AU - Engels, C

AU - Wagner, T

PY - 2004

Y1 - 2004

KW - Animals

KW - Humans

KW - Mice

KW - Tumor Cells, Cultured

KW - Drug Administration Schedule

KW - Mice, Nude

KW - Transplantation, Heterologous

KW - Lung Neoplasms/drug therapy

KW - Antineoplastic Agents, Alkylating/administration & dosage/therapeutic use

KW - Carcinoma, Non-Small-Cell Lung/drug therapy

KW - Cyclophosphamide/administration & dosage/analogs & derivatives/therapeutic use

KW - Neovascularization, Pathologic/prevention & control

KW - Animals

KW - Humans

KW - Mice

KW - Tumor Cells, Cultured

KW - Drug Administration Schedule

KW - Mice, Nude

KW - Transplantation, Heterologous

KW - Lung Neoplasms/drug therapy

KW - Antineoplastic Agents, Alkylating/administration & dosage/therapeutic use

KW - Carcinoma, Non-Small-Cell Lung/drug therapy

KW - Cyclophosphamide/administration & dosage/analogs & derivatives/therapeutic use

KW - Neovascularization, Pathologic/prevention & control

M3 - SCORING: Journal article

VL - 42

SP - 652

EP - 653

IS - 11

M1 - 11

ER -